Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the role of FLT3 inhibitors for treating patients with FLT3-mutated acute myeloid leukemia. Dr Perl discusses how FLT3 inhibitors should be incorporated into treatment regimens for patients receiving lower-intensity therapy.
Andrew Krivoshik, MD, PhD, Oncology Therapeutic Area Head at Astellas Pharma, discusses acute myeloid leukemia (AML) in the context of the COVID-19 pandemic. The prevalence of healthcare disparities…
In this video, Naval G. Daver, MD, a professor and director of the Leukemia Research Alliance Program, MD Anderson Cancer Center, Houston, Texas, and Uma Borate, MBBS, Acute…
Researchers from UC Davis Comprehensive Cancer Center discuss results from their recent study on long term complications adolescents and young adults face after treatment for acute myeloid leukemia…
In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
Courtney DiNardo, MD, MSCE, clinical researcher in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, presents promising…
